JCLA:抗核抗体检测----自动识别与传统方法的比较研究

2019-05-16 不详 网络

利用间接免疫荧光法(IIFA)检测抗核抗体(ANA)最早于1958年提出,但是至今作为ANA筛查的参考方法。目前,基于人类上皮(HEp‐2)细胞免疫荧光(IIF)的ANA标准高效解释的自动化处理和识别系统;欧洲模式套件(EUROPattern Suite, Euroimmun)在中国有售。

利用间接免疫荧光法(IIFA)检测抗核抗体(ANA)最早于1958年提出,但是至今作为ANA筛查的参考方法。目前,基于人类上皮(HEp2)细胞免疫荧光(IIF)ANA标准高效解释的自动化处理和识别系统;欧洲模式套件(EUROPattern Suite, Euroimmun)在中国有售。

在本研究中,通过与目视判读比较,评价该新系统在阳性/阴性分类、模式识别(包括同质、斑点、核仁、核点、细胞质和着丝粒模式)和效价评价方面的性能。

研究人员收集3681样本,肉眼观察和自动检查关于阳性/阴性有98.7%一致性介于(κ= 0.973)之间。单模式血清中模式识别正确率为94.6%。单个模式的自动识别效率因模式的不同而不同。自动确定的模式下,在1620例中有1071例是正确和完整的,在另外405例中是正确和有意义但不完整的(“主模式”),在所有案例中91.1%实现了主模式识别。参考滴度评价,认为下一个效价内的结果是一致的。在1603份经目测和自动检测均为阳性的血清中,1514份样本的效价一致,占94.4%

因此,本研究认为EUROPattern系统由于其性能特点,自动化程度高,结果可靠,适合临床应用,可以帮助临床实验室标准化IIF评价。

原始出处:

ZhiYan Li, RuiLin Han,Antinuclear antibodies detection: A comparative study between automated recognition and conventional visual interpretation

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1305170, encodeId=c75f13051e0b0, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat May 18 10:58:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535776, encodeId=5f6f1535e760f, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Sat May 18 10:58:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585639, encodeId=189b1585639d2, content=<a href='/topic/show?id=57b35536958' target=_blank style='color:#2F92EE;'>#抗核抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55369, encryptionId=57b35536958, topicName=抗核抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43717252607, createdName=mhzhuang@stu.e, createdTime=Sat May 18 10:58:00 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
    2019-05-18 marongnuan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1305170, encodeId=c75f13051e0b0, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat May 18 10:58:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535776, encodeId=5f6f1535e760f, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Sat May 18 10:58:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585639, encodeId=189b1585639d2, content=<a href='/topic/show?id=57b35536958' target=_blank style='color:#2F92EE;'>#抗核抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55369, encryptionId=57b35536958, topicName=抗核抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43717252607, createdName=mhzhuang@stu.e, createdTime=Sat May 18 10:58:00 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1305170, encodeId=c75f13051e0b0, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat May 18 10:58:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535776, encodeId=5f6f1535e760f, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Sat May 18 10:58:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585639, encodeId=189b1585639d2, content=<a href='/topic/show?id=57b35536958' target=_blank style='color:#2F92EE;'>#抗核抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55369, encryptionId=57b35536958, topicName=抗核抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43717252607, createdName=mhzhuang@stu.e, createdTime=Sat May 18 10:58:00 CST 2019, time=2019-05-18, status=1, ipAttribution=)]

相关资讯

抗核抗体阳性与复发性妊娠丢失有关吗?

前阵子生殖医学科的医生与我交流,讨论备孕患者抗核抗体(ANA)阳性与复发性流产的关系,如果育龄期女性备孕期间出现ANA阳性是否需要特殊治疗。

Ann Rheum Dis:风险队列中自身免疫性结缔组织病的预测:干扰素状态新二分法的预后价值

双因素的干扰素评分和家族史可以预测ANA阳性到AI-CTD的进展。这些干扰素评分有助于风险人群的AI-CTD分层。